Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)

Background Receptor activator of nuclear factor kappa-B ligand (RANKL) can directly promote tumor growth and indirectly support tumor immune evasion by altering the tumor microenvironment and immune cell responses. This study aimed to assess the prognostic significance of soluble RANKL in patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Bruno Vincenzi, Alessio Cortellini, Daniele Santini, Marco Russano, Giuseppe Tonini, Sonia Simonetti, Michele Iuliani, Silvia Cavaliere, Francesco Pantano, Leonardo Cristofani
Format: Article
Language:English
Published: BMJ Publishing Group 2024-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/6/e009432.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/6/e009432.full

Similar Items